Page last updated: 2024-11-12
zaragozic acid b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
zaragozic acid B: structure given in first source; a fungal metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9940176 |
| CHEMBL ID | 504845 |
| SCHEMBL ID | 6130350 |
| MeSH ID | M0211815 |
Synonyms (17)
| Synonym |
|---|
| zaragozic acid b |
| CHEMBL504845 , |
| bdbm50292415 |
| 146389-61-9 |
| unii-2af560r2hc |
| 2af560r2hc , |
| l-glycero-d-altro-pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-c-carboxy-8,9,10,12,13,14,15-heptadeoxy-10,12-dimethyl-15-phenyl-, 5-(6,12-tetradecadienoate), (5(6e,12e),7s,10xi,11xi,12xi)- |
| (1r,2s,3s,5s,6r,7r)-2,6-dihydroxy-5-[(e)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-enyl]-7-[(6e,12e)-tetradeca-6,12-dienoyl]oxy-4,8-dioxabicyclo[3.2.1]octane-1,2,3-tricarboxylic acid |
| gtpl6061 |
| SCHEMBL6130350 |
| zaragozic acid b [mi] |
| l-glycero-d-altro-pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-c-carboxy-8,9,10,12,13,14,15-heptadeoxy-10,12-dimethyl-15-phenyl-, 5-((6e,12e)-6,12-tetradecadienoate) |
| Q27089280 |
| (1s,3s,4s,5r,6r,7r)-4,7-dihydroxy-1-[(e)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-enyl]-6-[(6e,12e)-tetradeca-6,12-dienoyl]oxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid |
| (1s,3s,4s,5r,6r,7r)-4,7-dihydroxy-1-((e)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-en-1-yl)-6-(((6e,12e)-tetradeca-6,12-dienoyl)oxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid |
| HY-130331 |
| CS-0107332 |
Research Excerpts
Overview
Zaragozic acid B is a weak inhibitor of FPPase/GGPPase activities as compared to squalene synthase.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Zaragozic acid B is a weak inhibitor of FPPase/GGPPase activities as compared to squalene synthase." | ( Characterization of two distinct allyl pyrophosphatase activities from rat liver microsomes. Bansal, VS; Vaidya, S, 1994) | 1.01 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with zaragozic acid B leads to an eightfold increase in the amount of farnesol produced by C." | ( Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zaragozic acid B. Hornby, JM; Kebaara, BW; Nickerson, KW, 2003) | 0.88 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0002 | 0.0002 | 0.5521 | 10.0000 | AID336318 |
| Squalene synthase | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0002 | 0.0002 | 0.4543 | 4.2000 | AID336318 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID336093 | Inhibition of bovine Ras FPTase | 1993 | Journal of natural products, Nov, Volume: 56, Issue:11 | Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. |
| AID336318 | Inhibition of rat liver squalene synthase by liqiud scintillation counting | 1993 | Journal of natural products, Nov, Volume: 56, Issue:11 | Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. |
| AID1346813 | Rat squalene synthase (Lanosterol biosynthesis pathway) | 1993 | Proceedings of the National Academy of Sciences of the United States of America, Jan-01, Volume: 90, Issue:1 | Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||